The polypeptide antifungal agent (X-5079, C): further studies in 39 patients.

Grunberg and associates (1) in 1961, first described the polypeptide antifungal agent, X5079C (also referred to as R02-7758), produced by a species of Streptomyces, and active in experimental infections with Histoplasma capsulatum and Blastomyces dermatitidis in mice. Emmons (2) confirmed these observations and in addition found the drug active in infection with Coccidioides immitis and Sporotrichum schenckii in mice. These studies were followed by the demonstration of the drug's chemotherapeutic activity (3) and side effects ( 4) in 27' patients with systemic mycoses. The present report is a follow-up on these 27 and presents data on an additional12 patients.